Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19 : A CCC19-Registry Based Retrospective Cohort Study
BACKGROUND: Patients with sarcoma often require individualized treatment strategies and are likely to receive aggressive immunosuppressive therapies, which may place them at higher risk for severe COVID-19. We aimed to describe demographics, risk factors, and outcomes for patients with sarcoma and COVID-19.
METHODS: We performed a retrospective cohort study of patients with sarcoma and COVID-19 reported to the COVID-19 and Cancer Consortium (CCC19) registry (NCT04354701) from 17 March 2020 to 30 September 2021. Demographics, sarcoma histologic type, treatments, and COVID-19 outcomes were analyzed.
RESULTS: of 281 patients, 49% (n = 139) were hospitalized, 33% (n = 93) received supplemental oxygen, 11% (n = 31) were admitted to the ICU, and 6% (n = 16) received mechanical ventilation. A total of 23 (8%) died within 30 days of COVID-19 diagnosis and 44 (16%) died overall at the time of analysis. When evaluated by sarcoma subtype, patients with bone sarcoma and COVID-19 had a higher mortality rate than patients from a matched SEER cohort (13.5% vs 4.4%). Older age, poor performance status, recent systemic anti-cancer therapy, and lung metastases all contributed to higher COVID-19 severity.
CONCLUSIONS: Patients with sarcoma have high rates of severe COVID-19 and those with bone sarcoma may have the greatest risk of death.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Cancers - 14(2022), 17 vom: 05. Sept. |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 10.11.2022 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/cancers14174334 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM345949463 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM345949463 | ||
| 003 | DE-627 | ||
| 005 | 20231226030254.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers14174334 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1153.xml |
| 035 | |a (DE-627)NLM345949463 | ||
| 035 | |a (NLM)36077869 | ||
| 035 | |a (PII)4334 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wagner, Michael J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19 |b A CCC19-Registry Based Retrospective Cohort Study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 10.11.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a BACKGROUND: Patients with sarcoma often require individualized treatment strategies and are likely to receive aggressive immunosuppressive therapies, which may place them at higher risk for severe COVID-19. We aimed to describe demographics, risk factors, and outcomes for patients with sarcoma and COVID-19 | ||
| 520 | |a METHODS: We performed a retrospective cohort study of patients with sarcoma and COVID-19 reported to the COVID-19 and Cancer Consortium (CCC19) registry (NCT04354701) from 17 March 2020 to 30 September 2021. Demographics, sarcoma histologic type, treatments, and COVID-19 outcomes were analyzed | ||
| 520 | |a RESULTS: of 281 patients, 49% (n = 139) were hospitalized, 33% (n = 93) received supplemental oxygen, 11% (n = 31) were admitted to the ICU, and 6% (n = 16) received mechanical ventilation. A total of 23 (8%) died within 30 days of COVID-19 diagnosis and 44 (16%) died overall at the time of analysis. When evaluated by sarcoma subtype, patients with bone sarcoma and COVID-19 had a higher mortality rate than patients from a matched SEER cohort (13.5% vs 4.4%). Older age, poor performance status, recent systemic anti-cancer therapy, and lung metastases all contributed to higher COVID-19 severity | ||
| 520 | |a CONCLUSIONS: Patients with sarcoma have high rates of severe COVID-19 and those with bone sarcoma may have the greatest risk of death | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CCC19 | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a sarcoma | |
| 700 | 1 | |a Hennessy, Cassandra |e verfasserin |4 aut | |
| 700 | 1 | |a Beeghly, Alicia |e verfasserin |4 aut | |
| 700 | 1 | |a French, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Dimpy P |e verfasserin |4 aut | |
| 700 | 1 | |a Croessmann, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Vilar-Compte, Diana |e verfasserin |4 aut | |
| 700 | 1 | |a Ruiz-Garcia, Erika |e verfasserin |4 aut | |
| 700 | 1 | |a Ingham, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Schwartz, Gary K |e verfasserin |4 aut | |
| 700 | 1 | |a Painter, Corrie A |e verfasserin |4 aut | |
| 700 | 1 | |a Chugh, Rashmi |e verfasserin |4 aut | |
| 700 | 1 | |a Fecher, Leslie |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Cathleen |e verfasserin |4 aut | |
| 700 | 1 | |a Zamulko, Olga |e verfasserin |4 aut | |
| 700 | 1 | |a Trent, Jonathan C |e verfasserin |4 aut | |
| 700 | 1 | |a Subbiah, Vivek |e verfasserin |4 aut | |
| 700 | 1 | |a Khaki, Ali Raza |e verfasserin |4 aut | |
| 700 | 1 | |a Tachiki, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Nakasone, Elizabeth S |e verfasserin |4 aut | |
| 700 | 1 | |a Loggers, Elizabeth T |e verfasserin |4 aut | |
| 700 | 1 | |a Labaki, Chris |e verfasserin |4 aut | |
| 700 | 1 | |a Saliby, Renee Maria |e verfasserin |4 aut | |
| 700 | 1 | |a McKay, Rana R |e verfasserin |4 aut | |
| 700 | 1 | |a Ajmera, Archana |e verfasserin |4 aut | |
| 700 | 1 | |a Griffiths, Elizabeth A |e verfasserin |4 aut | |
| 700 | 1 | |a Puzanov, Igor |e verfasserin |4 aut | |
| 700 | 1 | |a Tap, William D |e verfasserin |4 aut | |
| 700 | 1 | |a Hwang, Clara |e verfasserin |4 aut | |
| 700 | 1 | |a Tejwani, Sheela |e verfasserin |4 aut | |
| 700 | 1 | |a Jhawar, Sachin R |e verfasserin |4 aut | |
| 700 | 1 | |a Hayes-Lattin, Brandon |e verfasserin |4 aut | |
| 700 | 1 | |a Wulff-Burchfield, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Kasi, Anup |e verfasserin |4 aut | |
| 700 | 1 | |a Reuben, Daniel Y |e verfasserin |4 aut | |
| 700 | 1 | |a Nagaraj, Gayathri |e verfasserin |4 aut | |
| 700 | 1 | |a Joshi, Monika |e verfasserin |4 aut | |
| 700 | 1 | |a Polimera, Hyma |e verfasserin |4 aut | |
| 700 | 1 | |a Kulkarni, Amit A |e verfasserin |4 aut | |
| 700 | 1 | |a Esfahani, Khashayar |e verfasserin |4 aut | |
| 700 | 1 | |a Kwon, Daniel H |e verfasserin |4 aut | |
| 700 | 1 | |a Paoluzzi, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Bilen, Mehmet A |e verfasserin |4 aut | |
| 700 | 1 | |a Durbin, Eric B |e verfasserin |4 aut | |
| 700 | 1 | |a Grivas, Petros |e verfasserin |4 aut | |
| 700 | 1 | |a Warner, Jeremy L |e verfasserin |4 aut | |
| 700 | 1 | |a Davis, Elizabeth J |e verfasserin |4 aut | |
| 700 | 0 | |a COVID-19 and Cancer Consortium |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancers |d 2009 |g 14(2022), 17 vom: 05. Sept. |w (DE-627)NLM198667213 |x 2072-6694 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2022 |g number:17 |g day:05 |g month:09 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/cancers14174334 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2022 |e 17 |b 05 |c 09 | ||